GlobeNewswire: Evoke Pharma, Inc. Contains the last 10 of 218 releaseshttp://www.globenewswire.com/External?Length=42024-03-28T22:14:23ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2024/03/21/2850636/0/en/Evoke-Pharma-Announces-Senior-Leadership-Transition-with-Promotion-of-Matthew-J-D-Onofrio-to-Chief-Executive-Officer.html?f=22&fvtc=4&fvtv=20175Evoke Pharma Announces Senior Leadership Transition with Promotion of Matthew J. D’Onofrio to Chief Executive Officer2024-03-21T20:15:59Z<![CDATA[SOLANA BEACH, Calif., March 21, 2024 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI® (metoclopramide) nasal spray, announced that Matthew J. D’Onofrio will be succeeding David A. Gonyer as Chief Executive Officer as of March 31, 2024 upon Mr. Gonyer’s departure for personal reasons. Mr. D’Onofrio currently serves as President and Chief Operating Officer.]]>https://www.globenewswire.com/news-release/2024/03/14/2846691/0/en/Evoke-Pharma-Reports-Fourth-Quarter-and-Full-Year-2023-Financial-Results.html?f=22&fvtc=4&fvtv=20175Evoke Pharma Reports Fourth Quarter and Full Year 2023 Financial Results2024-03-14T20:05:28Z<![CDATA[Fiscal year 2023 net product sales from prescriptions totaled approximately $5.2M, a 107% increase from 2022]]>Balance SheetEvoke Pharma, Inc.Statement of OperationsEvoke Pharma, Inc.https://www.globenewswire.com/news-release/2024/03/07/2842763/0/en/Evoke-Pharma-to-Report-Fourth-Quarter-and-Full-Year-2023-Results-on-March-14-2024.html?f=22&fvtc=4&fvtv=20175Evoke Pharma to Report Fourth Quarter and Full Year 2023 Results on March 14, 20242024-03-07T21:10:56Z<![CDATA[SOLANA BEACH, Calif., March 07, 2024 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases with an emphasis on Gimoti® (metoclopramide) nasal spray, today announced that the Company is scheduled to release its fourth quarter and full year 2023 on Thursday, March 14, 2024, after the market closes.]]>https://www.globenewswire.com/news-release/2024/02/14/2828998/0/en/Evoke-Pharma-Announces-Closing-of-7-5-Million-Public-Offering.html?f=22&fvtc=4&fvtv=20175Evoke Pharma Announces Closing of $7.5 Million Public Offering2024-02-14T12:30:17Z<![CDATA[Potential for Additional $22.5 Million in the Event of Exercise of Common Warrants in Full Potential for Additional $22.5 Million in the Event of Exercise of Common Warrants in Full]]>https://www.globenewswire.com/news-release/2024/02/09/2826743/0/en/Evoke-Pharma-Announces-Pricing-of-Underwritten-Public-Offering-of-up-to-30-Million.html?f=22&fvtc=4&fvtv=20175Evoke Pharma Announces Pricing of Underwritten Public Offering of up to $30 Million2024-02-09T12:30:48Z<![CDATA[SOLANA BEACH, Calif., Feb. 09, 2024 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI® (metoclopramide) nasal spray, announced today that it has priced an underwritten public offering led by Nantahala Capital Management, with participation by other fundamental investors, for gross proceeds of up to $30 million, that includes initial upfront funding of approximately $7.5 million, prior to deducting underwriting discounts and commissions and estimated offering expenses.]]>https://www.globenewswire.com/news-release/2023/11/27/2786159/0/en/Evoke-Pharma-Announces-FDA-Orange-Book-Listing-of-New-GIMOTI-Patent.html?f=22&fvtc=4&fvtv=20175Evoke Pharma Announces FDA Orange Book Listing of New GIMOTI Patent2023-11-27T13:30:26Z<![CDATA[GIMOTI now holds four listed patents with coverage through 2029 GIMOTI now holds four listed patents with coverage through 2029]]>https://www.globenewswire.com/news-release/2023/11/14/2780102/0/en/United-States-Patent-and-Trademark-Office-USPTO-Grants-Another-Formulation-Patent-Covering-GIMOTI.html?f=22&fvtc=4&fvtv=20175United States Patent and Trademark Office (USPTO) Grants Another Formulation Patent Covering GIMOTI2023-11-14T13:30:28Z<![CDATA[The Company Will Submit for FDA Orange-Book Listing in the Near Term The Company Will Submit for FDA Orange-Book Listing in the Near Term]]>https://www.globenewswire.com/news-release/2023/11/09/2777384/0/en/Evoke-Pharma-Reports-Third-Quarter-2023-Financial-Results.html?f=22&fvtc=4&fvtv=20175Evoke Pharma Reports Third Quarter 2023 Financial Results2023-11-09T13:30:44Z<![CDATA[38% Revenue Increase Compared to Q2 2023; 88% Increase Year-Over-Year]]>https://www.globenewswire.com/news-release/2023/10/31/2770197/0/en/Evoke-Pharma-EVERSANA-Unveil-Cost-Savings-Real-World-Data-Demonstrating-Meaningfully-Reduced-Healthcare-Costs-for-Patients-Using-GIMOTI-Over-Oral-Metoclopramide-Presented-at-the-Am.html?f=22&fvtc=4&fvtv=20175Evoke Pharma & EVERSANA Unveil Cost Savings Real-World Data Demonstrating Meaningfully Reduced Healthcare Costs for Patients Using GIMOTI Over Oral Metoclopramide Presented at the American College of Gastroenterology 20232023-10-31T12:30:34Z<![CDATA[Reduction in emergency department visits, hospitalizations and office visits caused diabetic gastroparesis patients and insurers to save over $15,000 for each patient in a six-month period by treating with GIMOTI versus oral metoclopramide Reduction in emergency department visits, hospitalizations and office visits caused diabetic gastroparesis patients and insurers to save over $15,000 for each patient in a six-month period by treating with GIMOTI versus oral metoclopramide]]>All-Cause HCRU visits in 6-month post-index period for NMCP and OMCP patientsImage 1All-Cause HRCU Costs between NMCP and OMCP patients over 6-month post index periodImage 2https://www.globenewswire.com/news-release/2023/10/18/2762379/0/en/Evoke-Pharma-s-Abstract-Entitled-Superiority-of-Nasal-Spray-Compared-to-Orally-Administered-Metoclopramide-in-Reducing-Healthcare-Costs-in-Treating-Diabetic-Gastroparesis-Patients-.html?f=22&fvtc=4&fvtv=20175Evoke Pharma’s Abstract Entitled “Superiority of Nasal Spray Compared to Orally Administered Metoclopramide in Reducing Healthcare Costs in Treating Diabetic Gastroparesis Patients” to Be Presented at The American College of Gastroenterology (ACG) 2023 Annual Meeting2023-10-18T12:30:57Z<![CDATA[Selected for a Distinguished Oral Plenary Presentation Selected for a Distinguished Oral Plenary Presentation]]>